Antitumor activity and antitumor mechanism of triphenylphosphonium chitosan against liver carcinoma
Source abstract
Abstract
N-(3-Carboxypropyl) triphenylphosphonium bromide chitosan (TPPB-CS) was synthesized and characterized by FTIR,1H NMR spectrometer, and Zeta potential. TPPB-CS showed a selectivity-toxicity among cancer cell lines (MG-63 and HepG2 cells) and mouse embryonic fibroblast cells (NIH3T3 cells). A significant effect on inhibiting cell migration in HepG2 cells was observed in vitro, and TPPB-CS could effectively inhibit tumor growth in H22-bearing mice in vivo. Furthermore, the distribution of cell cycle, the level of reactive oxygen species (ROS), mitochondrial transmembrane potential (Δψm), the expression of tumor necrosis factor α (TNF-α), and vascular endothelial growth factor (VEGF) were examined to investigate the antitumor mechanism of TPPB-CS. The results suggested that the antitumor activity of TPPB-CS may be attributed to delay the cell cycle in S phase, alter the ROS and Δψmlevel, as well as regulate the TNF-α and VEGF secretion. TPPB-CS can become a promising anticancer drug for clinical therapy.
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Synthesis and biological activity · Multicomponent Synthesis of Heterocycles · Synthesis and Characterization of Heterocyclic Compounds
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (50)
Show source-provided references
1. 10.1016/j.addr.2008.04.01610.1016/j.addr.2008.04.016 ↗
2. 10.1038/nature0720510.1038/nature07205 ↗
3. 10.1016/S0009-2509(03)00234-310.1016/S0009-2509(03)00234-3 ↗
4. 10.1021/acsami.5b0040510.1021/acsami.5b00405 ↗
5. 10.1016/j.cbi.2009.05.00610.1016/j.cbi.2009.05.006 ↗
6. 10.1016/j.carbpol.2013.05.03610.1016/j.carbpol.2013.05.036 ↗
7. 10.1006/gyno.1996.002610.1006/gyno.1996.0026 ↗
8. 10.1016/j.ijbiomac.2010.12.00610.1016/j.ijbiomac.2010.12.006 ↗
9. 10.1007/s11095-011-0566-710.1007/s11095-011-0566-7 ↗
10. 10.1039/C4RA07467J10.1039/C4RA07467J ↗
11. 10.1016/j.biomaterials.2013.01.07810.1016/j.biomaterials.2013.01.078 ↗
12. 10.1159/00001189710.1159/000011897 ↗
13. 10.1016/j.progpolymsci.2006.06.00110.1016/j.progpolymsci.2006.06.001 ↗
14. 10.1016/j.cbi.2009.12.00810.1016/j.cbi.2009.12.008 ↗
15. 10.1007/s00280-003-0726-510.1007/s00280-003-0726-5 ↗
16. 10.1016/j.ijbiomac.2014.08.03310.1016/j.ijbiomac.2014.08.033 ↗
17. 10.1021/bm060336m10.1021/bm060336m ↗
18. 10.1093/jn/134.4.94510.1093/jn/134.4.945 ↗
19. 10.1016/j.carbpol.2010.03.00910.1016/j.carbpol.2010.03.009 ↗
20. 10.1016/S0092-8674(04)00166-710.1016/S0092-8674(04)00166-7 ↗
21. 10.1016/j.addr.2009.09.00410.1016/j.addr.2009.09.004 ↗
22. 10.3322/caac.2133210.3322/caac.21332 ↗
23. 10.1039/c3tb20884b10.1039/c3tb20884b ↗
24. 10.1016/j.carbpol.2015.02.03910.1016/j.carbpol.2015.02.039 ↗
25. 10.1016/j.jconrel.2007.11.01810.1016/j.jconrel.2007.11.018 ↗
26. 10.1038/nature0762310.1038/nature07623 ↗
27. 10.1016/j.colsurfb.2011.02.02910.1016/j.colsurfb.2011.02.029 ↗
28. 10.1016/j.freeradbiomed.2011.02.03210.1016/j.freeradbiomed.2011.02.032 ↗
29. 10.1002/cncr.2659510.1002/cncr.26595 ↗
30. 10.1021/acs.molpharmaceut.5b0032010.1021/acs.molpharmaceut.5b00320 ↗
31. 10.1016/j.critrevonc.2010.08.00110.1016/j.critrevonc.2010.08.001 ↗
32. 10.1016/j.drup.2004.01.00410.1016/j.drup.2004.01.004 ↗
33. 10.1016/j.cbi.2011.07.00410.1016/j.cbi.2011.07.004 ↗
34. 10.1081/LPR-6495810.1081/LPR-64958 ↗
35. 10.1016/j.carbpol.2015.04.04010.1016/j.carbpol.2015.04.040 ↗
36. 10.1385/IR:23:2-3:26310.1385/IR:23:2-3:263 ↗
37. 10.1016/j.biomaterials.2012.03.03210.1016/j.biomaterials.2012.03.032 ↗
38. 10.1016/j.addr.2008.09.00110.1016/j.addr.2008.09.001 ↗
39. Phosphonium salts exhibiting selective anti-carcinoma activity in vitro
40. 10.1016/j.saa.2013.01.09010.1016/j.saa.2013.01.090 ↗
41. 10.1016/j.jhep.2013.07.00110.1016/j.jhep.2013.07.001 ↗
42. 10.1039/C3TB21348J10.1039/C3TB21348J ↗
43. 10.1016/j.matlet.2012.11.04510.1016/j.matlet.2012.11.045 ↗
44. 10.1002/open.20110000310.1002/open.201100003 ↗
45. 10.1158/0008-5472.CAN-08-156510.1158/0008-5472.CAN-08-1565 ↗
46. 10.1023/A:101134222062110.1023/A:1011342220621 ↗
47. 10.1002/mrm.113310.1002/mrm.1133 ↗
48. 10.1016/j.bmcl.2009.06.08610.1016/j.bmcl.2009.06.086 ↗
49. Promoting melanoma growth and metastasis by enhancing VEGF expression
50. 10.1038/ncomms594410.1038/ncomms5944 ↗